FertiTOX Main Assembly

15 & 28 January 2026

FertiTOX
Fertility after gonadotoxic treatments

Overview

FertiTOX
Fertility after gonadotoxic treatments

- *Review of published studies*
- *Data presentation (update 27.01.2025, only eligible records)*
- *Recruitment 2023 – 2025*
- *Follow-up (12-18 months after gonadotoxicity)*
- *Laboratory parameters*
- *Preliminary results*
- *PredictAYA (HORIZON grant)*
- *Next meetings, 15 & 24 June 2026*
- *FertiPROTEKT Berlin, 24 – 25 April 2026*

Review of Published Studies

FertiTOX
Fertility after gonadotoxic treatments

11 Systematic Reviews and Meta-Analyses (https://fertitox.com)
Risk/prevalence of infertility (95% CI)

Osteosarcoma	Female **5%**, Male **52**
Ewing's sarcoma	Female **13%**, Male **89%**
Soft tissue sarcoma	Female **71%**, Male **60%**
Testicular cancer	**14%** (9 – 21%)
Cerebral cancer	**20%** (10 – 34%)
Bone marrow transplant	Female **65%** (58 – 71%), Male **41%** (32 – 51%)
Colorectal cancer	Female **27%** (11 – 54%), Male **18%** (13 – 26%)
Breast cancer	**53%** (41 – 64%) for AMH <0.5 ng/mL
Hodgkin lymphoma	Female **21%** (15 – 28%), Male **49%** (36 – 62%)
Non-Hodgkin lymphoma	Female **23%** (14 – 35%), Male **35%** (27 – 44%)
Leukaemia (+ HSTC)	Female **70%** (5 – 83%), Male **59%** (28 – 85%)
Leukaemia (Ø HTSC)	Female **6%** (1 – 40%), Male **18%** (6 – 39%)
Uterine damage	Radiochemotherapy reduces uterine perfusion, size of the uterus and increases abortion rate

Overall Data by Disease

FertiTOX
Fertility after gonadotoxic treatments

Total of 1645 eligible patients

Malignant diseases

Other diseases



Overall Data by Sex

FertiTOX
Fertility after gonadotoxic treatments

Total of 1645 eligible patients

Males: 742

Female: 903



Analysis of Overall Data by Sex from 21 German Centres

FertiTOX
Fertility after gonadotoxic treatments

Total of 1089 eligible patients
506 males 583 females



Analysis of Overall Data by Sex from 16 Swiss Centres

FertiTOX
Fertility after gonadotoxic treatments

Total of 401 eligible patients
168 males 233 females



Analysis of Overall Data by Sex from 2 Austrian Centres

FertiTOX
Fertility after gonadotoxic treatments

Total of 146 eligible patients

65 males **81 females**



Centre Activity in REDCap

FertiTOX
Fertility after gonadotoxic treatments



Centres Activity by Year

Follow-up numbers in brackets

FertiTOX
Fertility after gonadotoxic treatments



Recruitment by Year

FertiTOX
Fertility after gonadotoxic treatments



Total of 873 eligible patients

- **Female: 514**
- **Males: 359**

Total of 751 eligible patients

- **Female: 388**
- **Males: 364**

Follow-up

Non-completion **Done** **Pending** **Future**



Reasons for non-completion:

- *Patient died*
- *Patient withdrew consent*
- *Patient was lost to follow-up*
- *Other reason (palliative, benignancy etc)*

Laboratory Parameters

FertiTOX
Fertility after gonadotoxic treatments

Primary endpoints that must be provided: **AMH concentration** and **SPERM concentration.**
The absence of other parameters is not a reason to exclude patients.

GONADOTOXICITY

BEFORE

Patient's data, fertility preservation measures

AMH

Menstruation parameters

Testosterone

Sperm parameters

Patient's data, pregnancy outcomes, WHOQOL-BREF

AMH + FSH + LH + E2

Menstruation parameters

Testosterone + FSH + LH

Sperm parameters

AFTER

Follow-up (12-18 months after)

FertiTOX
Fertility after gonadotoxic treatments

Organization of the 2nd Consultation

- **To centres:** Excel table with records with their estimated dates and any missing data
- **From centres:** medical letter from oncologist

Documentation of the 2nd Consultation → https://fertitox.com/

- Compact versions of the paper sheets (with ICD-10 list and WHOQOL-BREF)
- Translations (German, French, Italian, English)

Irene Marcu

irene.marcu@insel.ch

Kami Marie Schütz

Fertitox.FRAU@med.uni-heidelberg.de

Hodgkin Lymphoma – Groups

(n = 24)
± Immunotherapy

ABVD

Anthracycline based chemotherapy

Doxorubicin *Anthracycline*
Bleomycin *Antibiotic*
Vinblastine *Vinca alkaloid*
Dacarbazine *Alkylating agents*

BrECADD

Mixed chemotherapy with targeted therapy

Etoposide *Topoisomerase II inhibitor*
Cyclophosphamide *Nitrogen mustard*
Doxorubicin *Anthracycline*
Dacarbazine *Alkylating agents*

BEACOPP

Anthracycline & cyclophosphamide -based chemotherapy

Bleomycin *Antibiotic*
Etoposide *Topoisomerase II inhibitor*
Doxorubicin *Anthracycline*
Cyclophosphamide *Nitrogen mustard*
Vincristine *Vinca alkaloid*
Procarbazine *Alkylating agent*
Brentuximab vedotin *Antibody-drug conjugate*

Other

ABVD plus OPPA, COPP, MOPP, LOPP, Br

Mixed protocols such as ABVD, then dose escalation to BEACOPP



Hodgkin Lymphoma – Groups

(n = 24)
± Immunotherapy



Breast Cancer – Groups

(n = 54)
± Immunotherapy
± Endocrine therapy

EC-Tax

Anthracycline & cyclophosphamide -based chemotherapy

Epirubicin *and* ***Cyclophosphamide*** *(EC) followed by a* ***taxane****, such as*

- *either paclitaxel (Taxol)*
- *or docetaxel (Taxotere)*

EC-Tax + Carbo

Anthracycline, cyclophosphamide & platinum-based chemotherapy

Carbo-Tax

Taxane & platinum-based chemotherapy (TC or PC)

Other

Other combinations
CDK4/6 Inhibitor Ribociclib

Breast Cancer – Groups

(n = 54)
± Immunotherapy
± Endocrine therapy

FertiTOX
Fertility after gonadotoxic treatments



Before and After Gonadotoxicity

FertiTOX
Fertility after gonadotoxic treatments

Breast Cancer (n=42)

Age <35 Age ≥35



Hodgkin Lymphoma (n=14)

Age <30 Age ≥30

Testicular Cancer – Groups

FertiTOX
Fertility after gonadotoxic treatments

Good prognosis
Stage I
No chemotherapy

Good prognosis
Stage I
1 cycle

Seminoma

Carboplatin mono
Carboplatin *Platinum agent*

Non-seminoma

BEP
Bleomycin *Antibiotic (not anthracycline)*
Etoposide *Topoisomerase II inhibitor*
Carboplatin *Platinum agent*

≥ Moderate prognosis
Stages II-III
>1 cycle

Germ Cell Tumor (NSGCTs, seminoma)

BEP
Bleomycin *Antibiotic (not anthracycline)*
Etoposide *Topoisomerase II inhibitor*
Carboplatin *Platinum agent*

EP
Etoposide *Topoisomerase II inhibitor*
Cisplatin *Platinum agent*

Testicular Cancer – Groups

(n = 28)

FertiTOX
Fertility after gonadotoxic treatments



Before and After Gonadotoxicity

FertiTOX
Fertility after gonadotoxic treatments

Testicular Cancer (n=8, age: 25-37)

Hodgkin Lymphoma (n=6, age: 20-34)

Testosterone

(nmol/L)

Sperm Concentration

(10^6/mL)

Sperm Motility

(%, WHO A+B)

HORIZON Grant

European Commission | HORIZON EUROPE 2021-2027

Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer
HORIZON-MISS-2024-CANCER-01-05

"Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on infertility and reproductive health PredictAYA"

- The coordinator is **Prof Rodriguez** from Sweden
- There are **18 partners**, including Heidelberg, Innsbruck and Bern
- **8 work packages**
- **Total: € 7 millions**

The work packages you could get involved with, starting January 2026:

- **WP4** (around 1.1 Mio): Clinical research on ovarian toxicity from large cohorts across Europe (coordinated by FertiTOX members)
- **WP6**: Late effect of cancer therapies on fertility and reproduction in males

2 strategies:

- 1. Collection of data **(retrospectively)** from running 15 cohorts/11 countries of patients diagnosed with cancer **until December 31st 2025** (until June 2026?)
- 2. Collection of data **(prospectively)** in 11 countries of patients diagnosed with cancer **January 1st 2026**

Next meetings

(same content, different languages)

FertiTOX
Fertility after gonadotoxic treatments

FertiTOX → Main Assembly

DEUTSCH

- 15. Juni 2026, Montag 18:00
- 24. Juni 2026, Mittwoch 16:00

FertiTOX → Main Assembly (Swiss)

ENGLISH

- 15 June 2026, Monday 16:00
- 24 June 2026, Wednesday 18:00

Contact

FertiTOX
Fertility after gonadotoxic treatments

Switzerland

irene.marcu@insel.ch

michael.vonwolff@insel.ch

Germany

ariane.germeyer@med.uni-heidelberg.de

Fertitox.FRAU@med.uni-heidelberg.de

Austria

bettina.boettcher@i-med.ac.at

Sponsors

FertiTOX
Fertility after gonadotoxic treatments

krebsliga schweiz

Swiss cancer league

Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Deutsche Krebshilfe

IBSA
Caring Innovation

IBSA Institut Biochimique SA

Theramex
For Women, For Health

Theramex Switzerland GmbH

FERRING
PHARMACEUTICALS

Ferring Pharmaceuticals SA

20 Jahre FertiPROTEKT
Netzwerk für fertilitätsprotektive Maßnahmen

Save the Date – FertiPROTEKT
Plus a free German book for participants

Berlin, 24. – 25. April 2026

Registration & Program:

https://soft-consult.org/fp-arbeitstreffen-2026/

or

https://fertiprotekt.com/19-arbeitstreffen-fertiprotekt-24-25-04-2026/

Completely revised and extended new editions in 2026



Edition 2020